Study Summary
A Phase I, Multicenter study to evaluate the safety, tolerability, and Efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+T Lymphocyte Tumor Patients.
Want to learn more about this trial?
Request More InfoInterventions
Efficacy of LCAR-T2C CAR-T cellsDRUG
CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Oncology Department，The First Affiliated Hospital of USTC west district | Hefei | Anhui | China |
| Hematological Department, People's Hospital of Jiangsu Province | Nanjing | Jiangsu | China |
| Hematological Department，The First Affiliated Hospital of the Air Force Medical University | Xi’an | Shanxi | China |